A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)
Objective: To assess in vivo in Huntington’s disease (HD) changes in microglia activation state, due to treatment with laquinimod, as reflected by changes in 11C-PBR28…Automated pattern based classification in neuropathology proven parkinsonism
Objective: In patients with parkinsonism and uncertain differential diagnosis, an automated image-based algorithm can help to distinguish idiopathic Parkinson’s disease (IPD) from atypical parkinsonian syndromes…Brain 5-HT1 receptor binding in multiple system atrophy: A [18F]-MPPF PET study
Objective: The primary objective was to compare brain 5-HT1a receptor binding between patients with multiple system atrophy (MSA) and healthy controls (HC). The secondary objectives…Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET
Objective: We compared 2 novel MRI techniques: neuromelanin-sensitive MRI (NM-MRI) and susceptibility weighted imaging (SWI) with [11C]PE2I PET in order to establish their validity as biomarkers…Characteristics of the clinical and cerebral metabolism in Parkinson’s disease with atrophy in nucleus basalis of Meynert
Objective: We investigated characteristics of clinical and cerebral glucose metabolic abnormalities in Parkinson’s disease (PD) with atrophy in the nucleus basalis of Meynert (NBM). Background:…Mitochondrial Complex 1, Sigma 1 Receptor and Synaptic Vesicle protein 2A density in early de novo patients with Parkinson’s Disease: pilot PET data
Objective: In this study, we evaluated the density of Mitochondrial complex 1 (MC1), sigma 1 receptor (s1R) and Synaptic Vesicle protein 2A (SV2A) in early…Cerebrotendinous Xanthomatosis presenting Parkinsonism with bilateral iron accumulation in the basal ganglia
Objective: Cerebrontendinous xanthomatosis(CTX) is a treatable, autosomal recessive, lipid storage disorder disease. Herein, we present a case of CTX. It aims to refresh and improve…Decreased Cannabinoid Type 1 Receptor Density in Parkinson’s Disease: A [18F]FMPEP-d2 PET Study
Objective: To explore type 1 endocannabinoid receptor (CB1R) expression in subjects with Parkinson’s disease (PD) and healthy controls using [18F]FMPEP-d2 PET. Background: CB1Rs are expressed…Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease
Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease. Background: Recent work has shown loss of PDE10A expression…Tongue Myokymia and Earache as a unique presentation Associated with Local Tongue Pathology: A Case Report and Review of Literature
Objective: Here we report a rare case of tongue carcinoma presenting by abnormal movements in the tongue in form of myokymia, and Earache. Background: Fasciculations…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 33
- Next Page »